NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial...
NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H™25 Building a neuromuscular franchise with DNTH103; Phase 2 trial in Multifocal Motor...
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Dianthus), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody...
NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Dianthus), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1™24 with top-line results anticipated in 2H™25 $389 million of pro forma cash, including $216 million of net proceeds from a...
Dianthus Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)